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Feline large granular lymphocyte (LGL) lymphoma is an uncommon subtype of lymphoma char-
acterized by a grave prognosis and scarce response to chemotherapy. There are limited reports
on clinico-pathological and prognostic factors. One-hundred and 9 cats with newly diagnosed
LGL lymphoma that underwent initial staging (including hematology, serum biochemistry, tho-
racic radiographs and abdominal ultrasound), and followed-up were retrospectively evaluated.
LGL lymphoma was localized within the gastrointestinal tract with or without extra-intestinal
involvement in 91.7% of the cases, and at extra-gastrointestinal sites in 8.3%. Symptoms were
frequent. Anemia (31.2%) and neutrophilia (26.6%) were commonly observed, and 14 (12.8%)
cats had neoplastic circulating cells. Frequent biochemistry abnormalities included elevated
ALT (39.4%) and hypoalbuminemia (28.4%). Twenty (54.1%) of 37 cats had elevated serum
LDH. Treatment varied among cats, and included surgery (11%), chemotherapy (23%), corticos-
teroids (38.5%) and no treatment (27.5%). Median time to progression (MTTP) was 5 days, and
median survival time (MST) 21 days. MST was significantly shorter in the case of substage b,
circulating neoplastic cells, lack of chemotherapy administration, and lack of treatment
response. A small subset of cats (7.3%) survived more than 6 months, suggesting that a more
favorable clinical course can be found among LGL lymphoma patients.
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1 | INTRODUCTION
Feline large granular lymphocyte (LGL) lymphoma is a relatively rare,
morphologically distinct subtype of lymphoma that, among pets, is
mainly diagnosed in the feline specie. The origin of LGL lymphoma
has been linked to cytotoxic T- or NK lymphocytes, as documented
by positive immunoreactivity to T-cell or perforin-like markers.1
Systematic data on clinical characteristics, type of treatment, and
outcome in large cohorts of cats with LGL lymphoma are rare and all
reported series relatively small, with the largest study involving
45 cats.2 According to the published literature, LGL lymphoma occurs
more commonly in the small intestine, with a tendency to involve the
regional lymph nodes, other abdominal organs, peripheral blood
and/or bone marrow.2
There has been no substantial improvement in outcome over the
last 2 decades. In fact, all published studies show poor survival times
compared to other lymphoma subtypes, typically in the range of few
months, with scarce response to cytotoxic chemotherapy.2–5 Due to
the poor outcome and the presence of severe clinical signs, euthana-
sia is usually carried out soon after diagnosis.2–5 Nevertheless, trea-
ted individual cases are occasionally described as harboring a more
favorable prognosis.2,3,6
The aim of this retrospective study was to gather broader
clinico-pathological information on feline LGL lymphoma, which could
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be used to better define prognosis and improve the treatment deci-
sion process for this rare disease entity.
2 | MATERIAL AND METHODS
Members of the Italian Society of Veterinary Oncology (SIONCOV)
were asked to retrospectively search their records to identify cats
with newly diagnosed LGL lymphoma without any previous anti-
neoplastic treatment history for the disease (excluding steroids), for
which medical record information was sufficient to assess the extent
of involvement, treatment, treatment response and outcome. To be
enrolled, cats had to have at least a complete blood cell count (CBC),
serum biochemistry, thoracic radiographs and abdominal ultrasound.
Results of laboratory testing were classified as normal or abnor-
mal by comparing the results with the reference range of that partic-
ular laboratory.
For all cases, the cytological diagnosis of LGL lymphoma relied
on the presence of lymphoblasts containing the characteristic intracy-
toplasmic azurophilic granules, as previously described.7
Background information sought included: signalment (breed, sex,
age, weight), FIV/FeLV status, clinical signs and duration of signs, cor-
ticosteroids administered before diagnosis, staging tests performed,
involved sites, serum albumin, serum lactate dehydrogenase (LDH),
method of diagnosis, type of treatment, clinical response to treat-
ment, time to progression (TTP), survival time (ST), chemotherapy-
related toxicity graded according to VCOG criteria,8 and cause of
death.
Since remission status is a time-varying variable, and serial
follow-up imaging in the face of a fatal disease such as LGL may be
unrealistic, clinical response to treatment was mainly assessed physi-
cally. Thus, cats were divided into responders and non-responders
based on physical examination and clinical signs; imaging and labora-
tory findings were integrated if available. Responders were defined
as cats experiencing an improvement or resolution of clinical signs
after having started treatment coupled with complete remission and
partial remission (if imaging was performed), whereas non-responders
were defined as cats experiencing no symptom improvement and/or
stable disease or progressive disease (if imaging was performed). All
responses were required to last for at least 28 days.
3 | STATISTICAL ANALYSIS
TTP was calculated from the date of diagnosis to the date of first-
documented loco-regional and/or distant tumor progression. ST was
calculated from the date of diagnosis to the date of last visit or death.
Cats alive at data analysis closure or dead due to LGL-unrelated
causes were censored.
The following factors were investigated for prognostic signifi-
cance: breed, age, sex, weight, FIV/FeLV status, substage, symptom
duration, administration of corticosteroids before diagnosis, hemato-
logical alterations (anemia, neutrophilia, thrombocytopenia, hypoalbu-
minemia, increased LDH), tumor location (involved gastrointestinal
tract, extra-gastrointestinal sites, hepatosplenic involvement, thoracic
involvement, cavitary effusion, circulating large granular lymphocytes,
bone marrow infiltration), type of treatment (enterectomy, chemo-
therapy, corticosteroids, no treatment) and clinical response to
treatment.
The influence of these factors on TTP and ST was investigated
with a univariate and multivariate Cox regression analysis. Median
TTP and ST were assessed by means of Kaplan-Meier survival plots.
Statistical analysis was performed with SPSS Statistics v.19 (IBM,
Somers, New York). Significance was set at P ≤ .05.
4 | RESULTS
A total of 109 cats with LGL lymphoma were retrospectively
included. There were 90 (82.6%) domestic shorthair cats, 7 (6.4%)
Chartreux, 3 (2.8%) Persians, 3 (2.8%) Siamese cats, 2 (1.8%) Angora
cats, 2 (1.8%) Bengal cats, 1 (0.9%) Ragdoll and 1 (0.9%) Tonkinese.
There were 62 (56.9%) males and 47 (43.1%) females, all of which
were neutered. Median age was 10 years (range, 1-17 years), and
median weight was 3.8 kg (range, 2-8 kg). All cats have been tested
for FIV and FeLV: 3 (2.8%) cats were FeLV positive, and 2 (1.8%)
were FIV positive.
One-hundred and 7 (98.2%) cats had been experiencing symp-
toms for a median of 14 days (range, 1-270 days) before diagnosis.
Two (1.8%) cats were asymptomatic, whereas the information was
not available for 1 (0.9%) cat. Presenting symptoms are listed in
Table 1. Decreased appetite and anorexia were the most common
complaints, followed by vomiting, weight loss and lethargy/depres-
sion. Eighty-nine (83.9%) cats had more than 1 symptom before
diagnosis.
Nineteen (17.4%) cats had received corticosteroids before
diagnosis.
LGL lymphoma was diagnosed by means of cytology in
91 (83.5%) cats, and by means of cytology and histopathology in
18 (16.5%) cats (Figure 1). A T-cell immunophenotype was estab-
lished in 19 tumors (in 17 cases by means of immunohistochemistry
and in 2 cases by flow cytometric analysis), whereas the information
TABLE 1 Presenting symptoms of 107 symptomatic cats diagnosed
with LGL lymphoma. Eighty-nine cats had more than 1 symptom
before diagnosis
Symptom n (%)
Decreased appetite/anorexia 70 (66)
Vomiting 55 (51.9)
Weight loss 49 (46.2)
Diarrhea 21 (19.8)
Lethargy/depression 20 (18.9)
Icterus 10 (9.4)
Polyuria/ polydipsia 5 (4.7)
Dyspnea 4 (3.8)
Stypsis 4 (3.8)
Fever 2 (1.9)
Hematemesis 1 (0.9)
Hematochezia 1 (0.9)
Hypothermia 1 (0.9)
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was not available for all other cases. Notably, cytoplasmic granules
were not discerned in any case on hematoxylin and eosin-stained tis-
sue sections.
All cats had a minimum database, including CBC, serum biochem-
istry, thoracic radiographs and abdominal ultrasound.
When considering the CBC, 34 (31.2%) cats were anemic,
29 (26.6%) cats had neutrophilia, 13 (11.9%) had thrombocytopenia,
9 (8.3%) had lymphopenia, 7 (6.4%) had thrombocytosis, 4 (3.7%) had
neutropenia, 2 (1.8%) had eosinophilia, 1 (1.8%) had monocytosis and
1 (0.9%) had basophilia. In 14 (12.8%) cats, neoplastic cells were iden-
tified in the peripheral blood. In 37 (33.9%) cats, the bone marrow
was also examined, and 4 of them had neoplastic involvement. One
cat had marrow involvement and no circulating neoplastic cells.
Forty-4 (40.4%) cats had no hematological abnormalities.
The most common serum biochemistry abnormalities included
elevated alanine aminotransferase activity (n = 43; 39.4%), hypoalbu-
minemia (n = 31; 28.4%), elevated aspartate aminotransferase activity
(n = 30; 27.5%), elevated alkaline phosphatase activity (n = 26;
23.9%), azotaemia characterized by increased blood urea nitrogen or
creatinine, or both, (n = 23; 21.1%), hyperbilirubinaemia (n = 20;
18.3%), elevated glutamyltransferase activity (n = 14; 12.8%), and
hypocalcemia (n = 13; 11.9%). Twenty (54.1%) of the 37 cats in
which serum LDH was checked, had high serum levels. Forty cats
(36.7%) had no biochemical abnormalities.
LGL lymphoma was localized within the gastrointestinal tract
with or without extra-intestinal involvement in 100 (91.7%) cats, and
at extra-gastrointestinal sites in 9 (8.3%) cats.
Within the gastrointestinal tract, LGL lymphoma was localized to
the small intestine only (n = 88), large intestine only (n = 1), small and
large intestine (n = 8), stomach, small and large intestine (n = 1),
stomach and small intestine (n = 1), stomach and large intestine
(n = 1). Among the 100 cats with gastrointestinal LGL lymphoma,
85 had also extra-gastrointestinal involvement, including abdominal
lymph nodes (n = 73), liver (n = 34), spleen (n = 21), kidneys (n = 8),
lung and/or thoracic lymph nodes (n = 11), peripheral lymph nodes
(n = 2), skin (n = 1), pericardium (n = 1), and pancreas (n = 1). Ten
cats had peritoneal effusion, and 2 cats had pleural effusion.
When considering the 9 cats with extra-gastrointestinal LGL lym-
phoma, the disease was localized in the liver and spleen in 5 cats, in
the liver only in 2 cats, in the kidneys in 1 cat, and in the trachea
in 1 cat.
Among the 13 cats with circulating neoplastic cells, 10 had gas-
trointestinal LGL lymphoma and 3 had extra-gastrointestinal LGL
lymphoma.
Twelve (11%) cats underwent enterectomy; 9 of them received
CHOP-based dose-intense chemotherapy thereafter, 2 cats received
corticosteroids, and 1 cat received no further treatment. Twenty
(18.3%) cats received a CHOP-based dose-intense chemotherapeutic
protocol and 5 (4.7%) cats were treated with lomustine. Forty-2
(38.5%) cats received corticosteroids as single agent, and 30 (27.5%)
cats received no treatment at all.
The overall median TTP was 5 days (95% CI, 2.3-7.6). All cats but
1 was dead at data analysis closure due to their LGL lymphoma with
a median ST of 21 days (95% CI, 10.8-31.2). One cat was alive
70 days after diagnosis and was receiving no treatment.
All cats receiving some form of treatment (n = 79) were evalu-
able for response: 28 (35.4%) cats were considered responders, and
the remaining 51 (64.6%) non-responders.
When stratified according to treatment, cats undergoing enter-
ectomy survived for a median of 42 days (95% CI, 4.6-79.3). Cats
receiving CHOP-based chemotherapy had a median survival time of
60 days (95% CI, 53.0-67.0), and those receiving lomustine of 90 days
(95% CI, 47.0-132.9). Cats treated with corticosteroids had a median
survival time of 15 days (95% CI, 9.4-20.6), while those receiving no
treatment at all survived for a median of 5 days (95% CI, 0-13.8)
(P < .001; Figure 1).
FIGURE 1 Cat, mesenteric lymph node,
large granular lymphocyte lymphoma. (A, B)
Fine-needle aspirate showing a
proliferation of intermediate size
lymphocytes, many of which contain
coarse purple intracytoplasmic granules at
1 pole of the cell (May Grünwald-Giemsa).
(D, E) In the corresponding histological
sample, the neoplastic cells show a
moderate amount of brightly eosinophilic
cytoplasm, but granules are not visible
(Hematoxylin and eosin). Bars, 50 μm (A, C)
and 25 μm (B, D)
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When considering the 34 cats receiving chemotherapy, treatment-
related toxicity was only rarely reported. Altogether, there were 3 epi-
sodes of grade 1 and grade 2 gastrointestinal toxicity, respectively;
2 episodes of grade 1 neutropenia, and 4 episodes of grade 2 neutrope-
nia. One cat developed a tumor lysis syndrome after the first vincristine
administration, as demonstrated by clinical signs and laboratory results.
Twenty-four (70.6%) cats experienced no side effects.
On univariate analysis, factors significantly associated with an
increased risk of tumor progression were substage b, increased LDH,
lack of chemotherapy administration (either CHOP-based or lomus-
tine) and lack of response to medical treatment (Table 2). On multi-
variate analysis, only chemotherapy administration was still
significant (Table 3).
On univariate analysis, factors significantly associated with an
increased risk of tumor-related death were substage b, presence of
circulating neoplastic cells, lack of chemotherapy administration, and
lack of response to medical treatment (Table 4). On multivariate anal-
ysis, both circulating neoplastic cells (P = .05) and chemotherapy
administration (P < .001) retained significance (Table 5).
TABLE 2 Univariate Cox regression analysis of variables potentially
associated with increased risk of disease progression in 109 cats with
LGL lymphoma
Parameter
Median time to
progression
(days) HR
95% CI
PLower Upper
Purebred 1.250 0.758 2.063 .382
No 1
Yes 23
Sex 1.074 0.731 1.577 .717
Female 1
Male 7
Age 1.190 0.811 1.745 .373
>10 yearsa 1
≤10 years 5
Weight 1.384 0.934 2.051 .105
≤3.8 kga 1
>3.8 kg 7
FIV/FeLV status 1.571 0.633 3.897 .330
Positive 1
Negative 5
Symptoms
duration
1.092 0.742 1.608 .655
≤14 daysa 1
>14 days 7
Substage 3.091 1.098 8.698 .033*
b 1
a 70
Corticosteroids
pre-diagnosis
1.416 0.857 2.340 .175
Yes 1
No 14
Anemia 1.196 0.791 1.806 .396
Yes 1
No 10
Neutrophilia 1.204 0.780 1.860 .401
Yes 1
No 5
Thrombocytopenia 1.142 0.637 2.049 .656
Yes 1
No 7
Hypoalbuminemia 1.306 0.856 1.992 .216
Yes 1
No 14
Increased LDH 2.192 1.065 4.509 .033*
Yes 1
No 25
Gastrointestinal
tract
involvement
1.410 0.707 2.813 .330
No 1
Yes 5
Large intestine
and/or gastric
involvement
1.799 0.977 3.311 .059
Yes 1
(Continued )
TABLE 2 Continued
Parameter
Median time to
progression
(days) HR
95% CI
PLower Upper
No 10
Hepatosplenic
involvement
1.035 0.706 1.518 .861
Yes 1
No 10
Thoracic
involvement
1.029 0.550 1.925 .929
Yes 1
No 7
Cavitary effusion 1.051 0.573 1.930 .872
Yes 1
No 7
Circulating
neoplastic cells
1.773 0.993 3.165 .053
Yes 1
No 10
Bone marrow
infiltration
1.432 0.493 4.161 .509
Yes 15
No 5
Enterectomy 1.502 0.818 2.760 .190
No 1
Yes 34
Chemotherapy 3.398 2.114 5.461 <0.001*
No 1
Yes 50
Response to
medical
treatment
29.992 9.854 91.284 <0.001*
No 1
Yes 80
*Significant P value.
a Median value.
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There were 8 (7.3%) cats that survived more than 6 months: all
of them had a small intestine LGL with no peripheral blood involve-
ment, and 6 of them (75%) received a CHOP-based protocol. In the
population of cats surviving less than 6 months, the concomitant
presence of these 3 conditions was only observed in 20 out of
101 cases (19.8%; P = .002).
5 | DISCUSSION
This study represents the largest clinical study of feline LGL lym-
phoma, a rare lymphoproliferative disease characterized by clonal
TABLE 3 Multivariate Cox regression analysis of variables potentially
associated with increased risk of disease progression in 109 cats with
LGL lymphoma
HR
95% CI
PLower Upper
Substage b 3.495 0.452 27.047 .231
Increased LDH 1.393 0.644 3.012 .400
Chemotherapy administration 2.933 1.278 6.729 .011*
*Significant P value.
TABLE 4 Univariate Cox regression analysis of variables potentially
associated with increased risk of tumor-related death in 109 cats with
LGL lymphoma
Parameter
Median
survival
(days) HR
95% CI
PLower Upper
Purebred 1.280 0.767 2.137 0.344
No 21
Yes 29
Sex 1.165 0.788 1.721 0.433
Female 20
Male 24
Age 1.160 0.789 1.707 0.450
>10 yearsa 17
≤10 years 24
Weight 1.141 1.338 0.908 1.971
≤3.8 kga 20
>3.8 kg 24
FIV/FeLV status 1.072 0.435 2.640 0.880
Positive 30
Negative 21
Symptoms duration 1.043 0.709 1.534 0.830
≤14 daysa 21
>14 days 21
Substage 3.678 1.151 11.754 0.028*
b 20
a 210
Corticosteroids pre-
diagnosis
1.507 0.909 2.500 0.112
Yes 15
No 29
Anemia 1.377 0.911 2.082 0.130
Yes 21
No 21
Neutrophilia 1.245 0.800 1.938 0.332
Yes 21
No 20
Thrombocytopenia 1.327 0.739 2.383 0.344
Yes 10
No 21
(Continued )
TABLE 4 Continued
Parameter
Median
survival
(days) HR
95% CI
PLower Upper
Hypoalbuminemia 1.290 0.846 1.968 0.237
Yes 10
No 24
Increased LDH 1.788 0.891 3.588 0.102
Yes 10
No 37
Gastrointestinal tract
involvement
1.742 0.873 3.475 0.115
No 5
Yes 21
Large intestine and/or
gastric involvement
1.483 0.795 2.764 0.215
Yes 10
No 29
Hepatosplenic
involvement
1.106 0.753 1.623 0.608
Yes 20
No 21
Thoracic involvement 1.129 0.602 2.115 0.705
Yes 10
No 24
Cavitary effusion 1.021 0.533 1.957 0.949
Yes 10
No 24
Circulating neoplastic
cells
2.136 1.194 3.823 0.011*
Yes 5
No 24
Bone marrow
infiltration
1.419 0.487 4.131 0.521
Yes 30
No 30
Enterectomy 1.375 0.750 2.519 0.303
No 17
Yes 42
Chemotherapy 2.671 1.740 4.100 <0.001*
No 14
Yes 63
Response to medical
treatment
13.899 6.749 28.623 <0.001*
No 15
Yes 101
*Significant P value.
a Median value.
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expansion of cytotoxic T- or NK lymphocytes, as described in the
WHO histological classification of hematopoietic tumors of domestic
animals in 2002.9 Due to its rarity, LGL lymphoma is the poorest
characterized malignancy among lymphoid neoplasms, and the clinical
features have been described only in a small subset of studies. In
general, feline LGL lymphoma is perceived as a catastrophic disease
with an almost uniform mortality, for which no standard treatment is
currently available. In 2008, it was documented that cats with LGL
lymphoma typically die within 2 months despite treatment with dose-
intense chemotherapy.2 More recently, 9 cats with LGL lymphoma
receiving lomustine with or without L-Asparginase had a median ST
of 129 days.10
In our cohort of 109 cats with LGL lymphoma, the median age of
diagnosis was 10 years. Domestic shorthair cats were over-repre-
sented, and the overall incidence was similar between males and
females.
We confirm that cats with LGL lymphoma suffer from a very
poor prognosis with a median TTP of 5 days and a median ST of
21 days. In agreement with previous studies, LGL lymphoma was
most commonly located in the small intestine, abdominal lymph
nodes and liver.2,11 While the characteristic granules within lympho-
cytes were easily recognized by cytological evaluation in all cases,
histopathology failed to reveal discernible cytoplasmic granules,
thereby highlighting the pivotal role of cytology in diagnosing this
rare entity.
In the current series, symptoms and signs typically occurred
acutely, and cats experienced rapid disease progression and deterior-
ating condition. As previously reported2, non-specific signs such as
decreased appetite or anorexia, vomiting, weight loss, diarrhea and
lethargy were commonly described. The presence of symptoms (sub-
stage b) was significantly associated with shorter TTP and ST; never-
theless, only 2 cats were asymptomatic and this may have biased the
results. Substage b has been already reported as a negative prognos-
tic factor,12–15 as it probably reflects the poor tolerance to dose-
intense chemotherapy, leading to sub-optimal dosing and/or a prema-
ture treatment interruption, and the unwillingness of the owner to
pursue any treatment.
While hematological and biochemical abnormalities were quite
common, accounting for >50% of cats, none of them beside increased
LDH serum levels and circulating neoplastic cells reached prognostic
significance.
LDH is a cytoplasmic enzyme involved in anaerobic glycolysis
that reversibly catalyzes the transformation of pyruvate to lactate
and protons. The acidity generated by lactate and protons stimulates
cancer invasiveness and metastatic dissemination, leading to
chemoresistance and poor outcome.16 High serum LDH predicts
short survival in human diffuse large B-cell lymphoma and is 1 of the
5 risk factors included in the International Prognostic Index.17 Simi-
larly, increased serum LDH levels detected before and after treat-
ment have been shown to correlate with decreased survival in cats
and dogs with lymphoma.18–20 In this series, increased LDH was sig-
nificantly associated with a higher risk of disease progression, sup-
porting the evaluation of serum LDH level as a prognostic marker for
cats with LGL lymphoma.
Circulating neoplastic cells were significantly associated with a
shorter ST after univariate and multivariate analysis. Thus, the pres-
ence of circulating neoplastic cells was associated with disseminated
disease, correlating with significantly worse prognosis.
Nine of the 14 cats with circulating neoplastic cells had also their
bone marrow checked, and 4 of them had marrow infiltration. For
those cats without microscopic evidence of bone marrow infiltration,
the presence of a leukemic phase was likely a consequence of over-
spill of neoplastic LGL cells from visceral sites. Although lymphoma
overspill is an uncommon and poorly investigated phenomenon in
veterinary medicine, this is anecdotally reported mainly in patients
with gross tumor burden.21,22
The remaining 5 cats did not receive a bone marrow aspirate;
therefore, further comments would be speculative. One cat without
circulating neoplastic cells had bone marrow infiltration.
No standardized treatments are currently available to treat cats
with LGL lymphoma, and the optimal therapy remains unclear. In gen-
eral, treatment strategies consist of palliative medical treatment, sur-
gery, chemotherapy, or a combination of these, each applied
depending on the eligibility of the cat.
The greatest majority of the cats described here received either
corticosteroids as single agent or no treatment at all. Unlike dogs,
prior treatment with steroids did not impact prognosis in this series
of cats, and this is in agreement with a previous study.23 In our opin-
ion, this conservative approach may have been the result of clinicians’
skepticism and owner demotivation. In fact, the reported grave prog-
nosis together with the high incidence of gastrointestinal signs at
presentation (weight loss and anorexia) has likely discouraged owners
and clinicians form pursuing a more aggressive treatment approach.
Nevertheless, beside palliative treatment with steroids, a range
of therapeutic strategies has been used in the current series.
It has been described that individual cats can benefit from sur-
gery;24,25 however, this was not confirmed in the present cases.
Indeed, 12 cats underwent surgical debulking, followed by subse-
quent chemotherapy in 9 of them, with no significant improvement
of outcome. It may be possible that tumor resection does not benefit
cats with LGL lymphoma due to its peculiar biology, as previously
described,6,26–29 or the small number of cats may have rendered the
results statistically not significant.
In a previous study, LGL lymphoma has shown poor response to
standard chemotherapy regimens consisting of CHOP,2 while the
outcome was slightly better if lomustine with or without L-
asparaginase was administered.10 In the current series, lack of chemo-
therapy administration (either CHOP-based or lomustine) was signifi-
cantly associated with tumor progression and tumor-related death on
uni- and multivariate analysis. Additionally, lack of response to
TABLE 5 Multivariate Cox regression analysis of variables potentially
associated with increased risk of tumor-related death in 109 cats
with LGL lymphoma
HR
95% CI
PLower Upper
Substage b 2.966 0.932 9.439 0.066
Circulating neoplastic cells 1.794 1.000 3.221 0.050*
Chemotherapy administration 2.483 1.613 3.821 <0.001*
*Significant P value.
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medical treatment was significantly associated with tumor progres-
sion and tumor-related death, as already reported.23,26,29–31 It must
be stressed that despite the improvement in survival duration,
responses did not last, with a median survival time in cats receiving
chemotherapy of only 63 days, thereby revealing a very limited suc-
cess of medical treatment. Cats receiving lomustine as single agent
had a median ST of 90 days. Although this represents a minimal
improvement in survival duration, the efficacy of lomustine should be
evaluated in future prospective trials.
Notably, there were 8 cats surviving more than 6 months, sug-
gesting that the clinical behavior of these LGL lymphomas differs
from the typical clinical course. It was not possible to identify charac-
teristics unique to this sub-population; however, all the 8 cats had a
small intestine LGL with no peripheral blood involvement and 6 of
them had been treated with a CHOP-based protocol. Therefore, cats
with a more favorable clinical course can be found among LGL lym-
phoma patients. Additional studies should be performed to compare
the histological and molecular features of these tumors with those of
the more aggressive cases.
Also, no definitive distinction exists between LGL leukemia or lym-
phoma in cats, where the 2 diseases often overlap, presenting a similar
aggressive behavior, regardless if originating from T cytotoxic (CD3
+/CD8+) or NK lymphocytes. The clinical presentation and the poor
prognosis reported by previous studies and in our population recall that
of human patients with LGL lymphoproliferative disorders of NK rather
than CD3+/CD8+ phenotype; in the latter, in fact, an indolent behavior
and a favorable outcome can be expected. Conversely, in dogs, the
prognostic role of phenotype remains unclear in LGL leukemias and
lymphoma, as these tend to have an indolent course with lymphocytosis
lasting months to years. However, some dogs with LGL lymphomas
may undergo a more rapid progression leading to a grave outcome.32
This study has some limitations, including its retrospective nature
impeding the ability to access individual data and preventing treat-
ment standardization, and the subjective response assessment that
may have biased the classification of responders and non-responders.
Nevertheless, all cats had internal disease and serial imaging studies
were deemed impractical and expensive, more over in the face of a
rapidly fatal disease. Strength of the present study was that all cats
underwent initial staging, including thoracic radiographs and abdomi-
nal ultrasound, and none was lost to follow-up.
In conclusion, this study has identified the largest group of feline
LGL lymphoma published so far. The high mortality of LGL lymphoma
was associated not only with the very aggressive and often
chemotherapy-refractory nature of the disease, but also to the poor
condition of cats due to prolonged presence of severe symptoms,
possibly compromising the ability to deliver dose-intense chemother-
apy and/or to pursue aggressive surgery. Further negative prognostic
factors included circulating neoplastic cells, high LDH levels, lack of
chemotherapy administration, and lack of response to medical treat-
ment. A small subset of cats had a more indolent disease course with
survival times exceeding 6 months. Based on the above, we hypothe-
size that chemotherapy in the form of CHOP-based protocols or
CCNU as single agent may improve disease control and survival.
Future prospective studies are warranted to uniform therapy
recommendations.
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